濮阳东方妇科医院做人流收费非常低濮阳东方看妇科病很专业,濮阳东方医院妇科预约挂号,濮阳东方妇科医院价格非常低,濮阳东方妇科医院口碑好不好,濮阳东方男科咨询医生在线,濮阳东方收费非常低,濮阳东方医院男科治阳痿很便宜

BEIJING, Sep. 13 (Xinhuanet) --Experts have called for a national drug-control system after a nationwide deficit of a life-saving drug, which has lasted at least three months.Doctors at a Beijing hospital said some specialized hospitals, which perform hundreds of cardiac operations every month, have been paralyzed by their lack of protamine sulfate, which is commonly administered after heart surgery to reverse the anticoagulant effects of heparin.The earliest report of a shortage was in Hubei province on July 21. This was followed by reports of shortages in Guangdong, Shandong and Liaoning provinces.The Shandong newspaper, Qilu Evening News, quoted a regional sales manager, surnamed Zhuang, as saying the province had been allocated 150 doses of protamine sulfate after Shanghai No 1 Biochemical and Pharmaceutical Co Ltd recently resumed production of the drug."But its monthly use here is usually 10,000 doses," he said.The Ministry of Health has denied it is responsible for supplies of the drug and passed the buck to the State Food and Drug Administration, claiming the latter is responsible for the supervision of medicines.Shen Chen, head of the publicity office of the State Food and Drug Administration, said he was unaware of the shortage, but said the administration is responsible for the quality of medicines, not the supply."Development and reform authorities oversee the medicines' prices, while the industrial and commercial authorities oversee the storage. The food and drug departments only cover the approval and quality of medicines."Industry insiders said one of the reasons for the shortage was the low profit margin, which discourages companies from mass producing the drug."Some companies can't earn enough to recover their costs, therefore it is almost impossible to maintain their enthusiasm for continuing production," said Lu Guoping, secretary-general of the Shanghai Pharmaceutical Trade Association.Lu said the government should issue policies to prevent future shortages of such medicines to avoid possible nationwide public health incidents.Yi Shenghua, a lawyer at Beijing Yingke Law Firm, said the country should have a unified system to guarantee the normal supply of medicines that are widely used and drug manufacturers should fulfill their responsibilities to society, even though there is no law stipulating they should produce specific medicines.He came up with two ways to deal with the problem of companies only producing profitable drugs."The government can order businesses to manufacture a certain amount of cheap medicines. Or it can offer financial assistance to subsidize cheap, but life-saving medicines."

SAN FRANCISCO, Aug. 23 (Xinhua) -- The amount of malware targeted at devices based on Google's Android platform surged 76 percent in the second quarter over the previous three months in 2011, making it the most attacked mobile operating system, computer security firm McAfee said on Tuesday.A new McAfee study found that in the second quarter, Android- based malware surpassed Nokia's Symbian as the most popular target for mobile malware developers.While Symbian and Java ME, a platform designed for mobile devices and other embedded systems, remain the most targeted to date, the rapid rise in Android malware indicates that the platform could become an increasing target for cyber criminals McAfee said.Models pose with the new Samsung Galaxy S Android smartphone during its launch ceremony at the headquarters of Samsung Electronics in Seoul in this June 8, 2010 file photograph.It warned that the attacks on Android platform could affect everything from calendar apps, to text messages, and even a fake Angry Birds updates.According to the study, malware on mobile platforms is increasing steadily, often mimicking the same code as personal computer-based threats, as vast amount of personal and business data are now found on user's smartphones and other mobile devices."This year we've seen record-breaking numbers of malware, especially on mobile devices, where the uptick is in direct correlation to popularity," Vincent Weafer, senior vice president of McAfee Labs, said in a statement."Overall attacks are becoming more stealth and more sophisticated, suggesting that we could see attacks that remain unnoticed for longer periods of time," he noted.

BERLIN, June 1 (Xinhua) -- Germany's disease control center reported on Wednesday 365 new cases of the fatal enterohemorrhagic E. coli (EHEC), which marked a sharp rise since its outbreak in the middle of May.Twenty-five percent of the new cases involved the hemolytic- uremic syndrome (HUS), a serious complication resulting from E. coli infection that affects the blood and kidneys, Germany's Robert Koch Institute said.Until now 17 people in Europe, one in Sweden, the other in Germany have been killed by the deadly disease, while the source of the infection was still not identified.According to the data of Robert Koch Institute, at present 470 patients are suffering from HUS due to the infection, raising concerns that the death toll could be even higher in the future.Germany's Agriculture and Consumer Protection Minister Ilse Aigner defended Germany's previous alert on cucumbers from Spain on Wednesday."The fatal strain of EHEC bacteria was indeed found on Spanish cucumbers. According to the European rules, a quick warning must be sent out," she told a local TV station.Laboratory tests in Hamburg on Tuesday overthrew the previous finding that Spanish cucumbers were the sources of the outbreak.As a result of the alert, Europe and Russia imposed bans on Spanish vegetables, leaving Spanish farmers a loss of 200 million euros (287.5 million U.S. dollars) a week.Spain has expressed its intention to take possible legal actions against authorities in Hamburg and ask for compensations from Germany and the European Union.

WELLINGTON, June 7 (Xinhua) -- Scientists in New Zealand have developed a new drug to fight previously untreatable hypoxic cancer tumors, which form in areas of the body starved of oxygen.The researchers at the Auckland University have entered an agreement for the clinical development of CEN-209, which was developed over 10 years of research, said a statement from the university Tuesday.CEN-209 was designed to enhance the effectiveness of radiotherapy and chemotherapy in solid hypoxic tumors, which were resistant to standard cancer therapies, said the statement. In lung cancer patients for example, about half of tumors had hypoxic regions.The new drug worked by damaging the DNA of hypoxic cancer cells, while leaving normal, healthy tissues alone.CEN-209 was designed and created by researchers at the university's Auckland Cancer Society Research Centre (ACSRC), using computer models of drug transport within tumors to accurately predict the anti-tumor activity of the drugs."Our computer models of drug transport developed in-house allowed the synthetic chemists to test their design theories and considerably shortened the discovery process," said Associate Professor Michael Hay, who led the ACSRC research chemists."CEN-209 improves markedly on previous agents in this class in terms of its ability to penetrate tumors, and this is reflected by its improved activity in the laboratory, when combined with long or short courses of radiotherapy," said researcher Professor Bill Wilson.Under the agreement between the university's Auckland UniServices Ltd. and California-based Centella Therapeutics, Inc., a subsidiary of Varian Medical Systems, Inc., Centella will have exclusive rights to CEN-209, which it will develop and trial with Cancer Research UK.The work on CEN-209 is the culmination of a program initiated with funding from the U.S. National Cancer Institute, and more recently from the Maurice Wilkins Centre for Biodiscovery. Ongoing preclinical research on CEN-209 and a backup compound was funded by grants from the Auckland Medical Research Foundation, Genesis Oncology Trust and Health Research Council of New Zealand, said the statement.

BEIJING, Aug. 24 (Xinhuanet) -- Facebook said it is overhauling its privacy settings to give members easier, more precise control over who sees posts, photos and other content over the vast social network.Starting Thursday, Facebook is rolling out new privacy tools that are placed with each piece of content, replacing options that are now buried in overall account settings.Privacy has been a consistently sticky problem for the Palo Alto firm, which has felt the heat from privacy advocates and government regulators. And recently, Facebook faced stiffer competition from Google's new Google+ social network, which was hailed for including a "circles" feature with easy-to-use privacy settings.Instead of vague labels such as "everyone," which have been mistaken for a Facebook member's social network instead of anyone on the Internet, the new system will include more precise words such as "public.""You have told us that 'who can see this?' could be clearer across Facebook, so we have made changes to make this more visual and straightforward," Chris Cox, Facebook's vice president of product, said in blog post."The main change is moving most of your controls from a settings page to being inline, right next to the posts, photos and tags they affect. Plus there are several other updates here that will make it easier to understand who can see your stuff (or your friends') in any context," Cox said.While privacy advocates reserved judgment until the new settings are actually released, they were optimistic the changes will benefit consumers."These changes do make me feel very confident in the direction that Facebook is going and the way they are thinking about privacy," said Erica Newland, policy analyst for the Center for Democracy & Technology in Washington, D.C.